lunes, 19 de enero de 2015

Emerging biomarkers in head and neck cancer in the era of genomics : Nature Reviews Clinical Oncology : Nature Publishing Group

Figure 1: Molecular pathogenesis of EBV-related NPC.

EBV genome products are shown in red. In patients at high risk of NPC, LOH at 9p and 3p is found before EBV infection and might predispose to NPC.⁷After EBV infection, BART microRNAs inhibit transcription of genes related to apoptosis…

Emerging biomarkers in head and neck cancer in the era of genomics

Nature Reviews Clinical Oncology

12,

11–26

(2015)

doi:10.1038/nrclinonc.2014.192

Published online: 18 November 2014

Abstract

Head and neck cancer (HNC) broadly includes carcinomas arising from the mucosal epithelia of the head and neck region as well as various cell types of salivary glands and the thyroid. As reflected by the multiple sites and histologies of HNC, the molecular characteristics and clinical outcomes of this disease vary widely. In this Review, we focus on established and emerging biomarkers that are most relevant to nasopharyngeal carcinoma and head and neck squamous-cell carcinoma (HNSCC), which includes primary sites in the oral cavity, oropharynx, hypopharynx and larynx. Applications and limitations of currently established biomarkers are discussed along with examples of successful biomarker development. For emerging biomarkers, preclinical or retrospective data are also described in the context of recently completed comprehensive molecular analyses of HNSCC, which provide a broad genetic landscape and molecular classification beyond histology and clinical characteristics. We will highlight the ongoing effort that will see a shift from prognostic to predictive biomarker development in HNC with the goal of delivering individualized cancer therapy.

View full text